Partner With Us NRI

Sequent Scientific Ltd share Price

Company details

6M Return -22.74%
1Y Return -31.44%
Mkt Cap.(Cr) 1,847.05
Volume 826,205
Div Yield 0.00%
OI Chg %
Volume 826,205

Open Free Trading Account Online with ICICIDIRECT

Sequent Scientific Ltd.

Q2FY23 Quarterly Result Announced for Sequent Scientific Ltd.

 Pharmaceutical company SeQuent Scientific announced Q2FY23 results:

  • Revenues Rs 3,376 million in Q2FY23 and Rs 6,789 million in H1FY23
  • EBITDA (pre-ESOP) Rs 150 million in Q2FY23 and Rs 351 million in H1FY23
  • EBITDA Rs 51 million in Q2FY23 and Rs 161 million in H1FY23

Rajaram Narayanan, Managing Director, stated, “Q2FY23 has been challenging owing to macro environment headwinds even though we continue to see strong performance in select markets. While the overall business grew 2.9% in constant currency terms, the reported revenue declined 3.7% over Q2FY22. EBITDA before ESOP costs stood at Rs 150 million for Q2. Normalised margins (after one-time costs & currency impact) are trending upwards.

The API business was subdued due to a slower revival in demand and delays in concluding a few contracts. Our efforts in developing strong partnerships with the top 10 animal health global companies are yielding results and we are confident to restore momentum in this business. We continue to invest in API business across key projects and upgrade our facilities. Our Mahad facility received the prestigious EcoVadis Sustainability Silver Medal and certificate, following by the recent TÜV Nord ISO certifications for Environment, Health & Safety (EHS) in Q1, further validating our commitment to global EHS standards.

Our Formulations business grew by 14.8% on constant currency basis, driven by a strong performance in emerging markets and India. We continue to accelerate our efforts in these markets while simultaneously implementing profitability improvement initiatives in our businesses in Europe & Turkey. We continue to believe in SeQuent’s robust business model and are executing on key growth levers.

We are pleased to announce that we signed a definitive agreement on November 7, 2022, to acquire 100% stake in Tineta Pharma Pvt Ltd, a company incorporated in India. This acquisition, which is in line with our strategic priority to scale up India formulations business, will be EBITDA accretive and gives a significant boost to our SeQuent 2.0 plans.

While the business environment is challenging due to high input costs, currency deterioration in some markets and subdued demand, the company is undertaking multiple initiatives to prioritise growth segments, remain competitive on costs and deepen our engagement with customers. We continue to invest in capabilities and talent required to deliver our ambitious plans and are confident that our initiatives would create a sustainable, long-term advantage for the company as it returns to higher levels of profitable growth.”


Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Sequent Scientific Ltd Stocks COMPARISION


Equity Capital: 683.27 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 4,188.45 35,755.27
LAST 3M 16,061.94 57,887.59
LAST 6M 62,190.55 42,497.37
LAST 12M 116,352.25 89,431.64

Sequent Scientific Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Sequent Scientific Ltd. is a leading manufacturer and exporter of specialized quality formulations aimed at fulfilling the diverse demands of the pharmaceutical industry. It manufactures formulations belonging to the anthelmintic and anti-parasitic segments. It was incorporated in 1985 with its headquarters in Mumbai. During FY 2021-2022, the company’s total revenue was Rs 1,423.66 crore, up 3.92% from the previous financial year, 2020-2021. On 29 August 2022, its market capitalization stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/sequentscientific/PID01" 2,788 crore.  

    Sequent Scientific Ltd.’s shares are listed on the Bombay Stock Exchange with the code 512529, and on the National Stock Exchange with the code SEQUENT.  

    Sequent Scientific Ltd. is amongst the top 20 global animal health companies. It is backed by The Carlyle Group, a global investment firm. The company has eight manufacturing facilities across Turkey, Europe, Brazil, and India. The Vizag site in India is the country’s only USFDA-approved dedicated veterinary API facility.  

    The company’s shareholding pattern at the end of the June 2022 quarter showed a promoter stake of 52.79%, foreign institutional investor stake of 6.45%, domestic institutional investor stake of 2.26%, and public stake of 38.1%. The entire promoter share belongs to CA Harbor Investments. During the June 2022 quarter, promoter holdings decreased from 53.02% to 52.79%, mutual fund holdings reduced from 0.30% to 0.29%, and FII holdings increased from 5.84% to 6.45%.  

    Mr Manish Gupta is the company’s managing director and CEO. Its board members include Dr Kamal K Sharma, Mr Sharat Narasapur, Mr Neeraj Bharadwaj, Mr Rahul Mukim, Dr Fabian Kausche, Mr Gregory John Andrews, and Dr (Mrs) Kausalya Santhanam. The auditors of the company are S R B C & Co. LLP. On 30 June 2022, the company had a total of 24.94 crore shares outstanding.  

    On 29 August 2022, the company’s share price closed at Rs 112.50 on BSE and at Rs 111.80 on NSE. The 52-week high for Sequent Scientific Ltd.’s share price was Rs 239.70, and the 52-week low for the company’s share price was Rs 82.  

    The company’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd.  

    As of August 2022, White Oak Capital Flexi Cap Fund had a 0.45% stake in Sequent Scientific Ltd. 

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose 

Registered Address

301 Dosti Pinnacle 3rd Floor, Plot E7 Road No 22 Wagle Indl, Thane, Maharashtra, 400604

Tel : 91-022-41114777
Email : investors:sequent.in
Website : http://www.sequent.in

Adroit Corp. Services Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 512529
Book Closure Date (Month) :
BSE Group : A
ISIN : INE807F01027

FAQ’s on Sequent Scientific Ltd Shares

You can buy Sequent Scientific Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Sequent Scientific Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 07, 2023 03:57 PM the closing price of Sequent Scientific Ltd was ₹ 74.05.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jun 07, 2023 03:57 PM, the market cap of Sequent Scientific Ltd stood at ₹ 1,847.05.

The latest PE ratio of Sequent Scientific Ltd as of Jun 07, 2023 03:57 PM is 0

The latest PB ratio of Sequent Scientific Ltd as of Jun 07, 2023 03:57 PM is 0.38

The 52-week high of Sequent Scientific Ltd is ₹ 132.50 while the 52-week low is ₹ 61.80

Download Our App

market app
market app